BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

AccessClosure, Inc. Presents Results From Pivotal Trial For Novel Vascular Closure Technology


10/19/2005 5:08:43 PM

MOUNTAIN VIEW, Calif., Sept. 30 /PRNewswire/ -- AccessClosure, Inc. today announced results from its MatrixVSG(TM) System Pivotal Trial. The trial enrolled 630 patients at 13 sites in the United States to evaluate the safety and efficacy of the synthetic hydrogel vascular closure technology designed to seal femoral artery punctures after interventional and diagnostic endovascular procedures. Patients were randomized 2:1 to standard compression, which is considered to be the gold standard for vascular closure.

Worldwide, over 12 million arterial punctures each year require closure and groin management following interventional or diagnostic endovascular procedures. However, broad acceptance of currently approved closure devices has been slow due to safety and efficacy concerns when compared to manual compression.

The Matrix VSG System has been developed by AccessClosure, Inc. to seal femoral arterial puncture sites after endovascular procedures through the simultaneous injection of two synthetic fluid components into the tissue tract of the access-site. Once the two fluids are delivered, they mix subcutaneously (within the tissue tract) to form a hydrogel sealant over the arterial access-site, around the artery and in the tissue tract. The fluids are comprised of fully synthetic and non-thrombogenic PolyEthylene-Glycol (PEG), a biomaterial commonly used in medical devices and pharmaceutical products. The PEG hydrogel is designed to be fully resorbable in the body in less than 30 days, leaving behind only a completely healed puncture-site. The material is designed so that if the PEG hydrogel is injected into the artery it will dissipate in flowing blood, thus minimizing catastrophic closure complications.

Final results from the Matrix(TM) VSG System trial were presented today at the Transcatheter Cardiovascular Therapeutics (TCT) 16th Annual Scientific Symposium 2004 meeting in Washington DC by Mark A. Turco, M.D., Director of the Center for Cardiac and Vascular Research at Washington Adventist Hospital, Takoma Park, MD and Principal Investigator for the Matrix VSG(TM) Trial.

"We have successfully met the study safety and effectiveness endpoints demonstrating that this technology provides improved hemostasis and ambulation times with a safety profile non-inferior to standard compression, as per our study protocol," said Dr. Turco. "The times to hemostasis and ambulation were very impressive and thus support use of a hydrogel-based closure technology," continued Turco.

"The data that we are seeing today are consistent with data we've seen in our European clinical trials and we are excited to share the results," said Fred Khosravi, President & CEO of AccessClosure. "The successful completion of this study serves as a platform for AccessClosure to complete its Pre- Market Approval (PMA) application and also to bring forward a new pipeline of products for access-site management," continued Khosravi.

"What is different about this novel technology is that it provides secure and rapid extravascular closure with no animal by-products and bioresorbs within one month. All of these are recognized as important features for treating interventional and diagnostic patients who could benefit from the use of a closure device," added Turco.

AccessClosure expects final submission of the Pre-Market Approval (PMA) for Matrix VSG System to the US Food and Drug Administration in early fall, 2004.

About AccessClosure

AccessClosure is a privately-held company, based in Mountain View, CA and funded by ONSET Ventures and Three Arch Partners. The company is dedicated to developing next generation vascular access-site management technologies that address the unmet clinical need of safe, effective and simple groin management following interventional and diagnostic endovascular procedures.

AccessClosure, Inc.

CONTACT: Heather Simonsen, Corporate Communications of AccessClosure,Inc., +1-650-864-5424 or info@accessclosure.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES